Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin – Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes
Open Access
- 1 January 2017
- journal article
- review article
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 13 (2)
- https://doi.org/10.17925/ee.2017.13.02.62
Abstract
The last decade has witnessed the role of dipeptidyl peptidase-4 (DPP-4) inhibitors in producing a conceptual change in early management of type 2 diabetes mellitus (T2DM) by shifting emphasis from a gluco-centric approach to holistically treating underlying pathophysiological processes. DPP-4 inhibitors highlighted the importance of acknowledging hypoglycaemia and weight gain as barriers to optimised care in T2DM. These complications were an integral part of diabetes management before the introduction of DPP-4 inhibitors. During the development of DPP-4 inhibitors, regulatory requirements for introducing new agents underwent substantial changes, with increased emphasis on safety. This led to the systematic collection of adjudicated cardiovascular (CV) safety data, and, where 95% confidence of a lack of harm could not be demonstrated, the standardised CV safety studies. Furthermore, the growing awareness of the worldwide extent of T2DM demanded a more diverse approach to recruitment and participation in clinical trials. Finally, the global financial crisis placed a new awareness on the health economics of diabetes, which rapidly became the most expensive disease in the world. This review encompasses unique developments in the global landscape, and the role DPP-4 inhibitors, specifically vildagliptin, have played in research advancement and optimisation of diabetes care in a diverse population with T2DM worldwide.Keywords
This publication has 67 references indexed in Scilit:
- SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugsExpert Review of Clinical Pharmacology, 2017
- Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studiesDiabetes, Obesity and Metabolism, 2017
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 2016
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusThe New England Journal of Medicine, 2013
- Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairmentInt. Journal of Clinical Pharmacology and Therapeutics, 2013
- Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal ImpairmentDiabetes Therapy, 2013
- One‐year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairmentDiabetes, Obesity and Metabolism, 2012
- Understanding the inter‐relationship between improved glycaemic control, hypoglycaemia and weight change within a long‐term economic modelDiabetes, Obesity and Metabolism, 2010
- Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during RamadanInternational Journal of Clinical Practice, 2009
- The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: The VA Cooperative Study in diabetesJournal of Diabetes and its Complications, 2006